New monthly shot aims to control kidney disease
NCT ID NCT07020923
First seen Apr 22, 2026 · Last updated Jun 15, 2026 · Updated 8 times
Summary
This study tests a drug called atacicept given once a month to adults with IgA nephropathy, a kidney disease. The goal is to see if it lowers certain proteins linked to the disease and is safe. About 90 people will take part in this Phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BERGER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vera Therapeutics
Brisbane, California, 94005, United States
Conditions
Explore the condition pages connected to this study.